PHARMACOLOGY OF FOREBRAIN SEROTONIN RECEPTORS
PHARMACOLOGY OF FOREBRAIN SEROTONIN RECEPTORS
批准号:
3416648
负责人:
RICHARD H ALPER
金额:
$13.89万
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-04-01 至 1996-03-31
关键词:
amygdala autoradiography baroreceptors blood pressure brain mapping cardiovascular function cardiovascular pharmacology consciousness heart rate hemodynamics homeostasis hormone regulation /control mechanism hypothalamus kidney circulation laboratory rat mesenteric artery microinjections neuroendocrine system neuropharmacology paraventricular nucleus preoptic areas prosencephalon receptor sensitivity serotonin serotonin inhibitor serotonin receptor stimulant /agonist
中文摘要
在分子、细胞和生物化学方面都取得了进展
5-羟色胺(5-HT)受体的药理学,但其功能
意义是不确定的。 总体目标是选择性地使用
用于评估体内前脑5-HT受体亚型的药物。
本研究假设:选择性激活5-HT受体阻断剂,
在离散的大脑区域中的亚型将引发独特的模式,
自主神经、血液动力学和神经内分泌反应
心血管功能 具体目标是将药物微量注射到
下丘脑前部、室旁核、视前内侧核
在清醒的,不受限制的大鼠中,区域和中央杏仁核:1)描述
前脑5-HT_(1A)、5-HT_(2)和5-HT_(3)受体在心血管
功能,和2)确定神经和/或激素介质的
应答 主要使用的5-HT激动剂是8-OH-DPAT [8-OH-DPAT]。
羟基-2-二正丙基氨基)四氢化萘]对5-HT 1A受体,DOI
[(正/负)-1-(2-5-二甲氧基-4-碘苯基)-2-氨基丙烷HCl],用于5-
HT 2/1C受体和2-甲基5-HT 5-HT 3受体。 其它激动剂
为了提供更详细的受体表征,可以包括
flesinoxan和5-羧酰胺色胺(5-HT 1A),DOB [(加/减)-1-(2-
5-二甲氧基-4-溴苯基)-2-氨基丙烷HBr](5-HT 2/1C)和
苯基双胍(5-HT 3)。 主要使用的拮抗剂是
用于5-HT 1A受体的螺哌隆、用于5-HT 2受体的酮色林和ICS
205-930用于5-HT 3受体。 同样,更详细的表征可以
包括使用(-)吲哚洛尔、(+)吲哚洛尔和甲硫替平(5-HT 1A),
LY 53857和螺哌隆(5-HT 2/1C),以及MDL 72222和昂丹司琼(5-HT 3)。
这些药物的适当使用与描述
扩散距离使用放射自显影技术以及
自主神经和激素拮抗剂改变反应的能力将
允许定量体内评估5-HT
前脑中的受体亚型调节动脉压、心脏
心率、心输出量和肾、髂和上级肠系膜血液
流动。 为了将反射与直接反应分开,
将在慢性手术压力感受器
传入神经阻滞 总的来说,实验将提供详细的
关于脑区域、受体亚型和神经体液的信息
5-HT受体调节心血管稳态的机制。
这些研究将提供关于
5-HT受体亚型在离散前脑区的功能,
体外生物化学、细胞和分子生物学
药理学
英文摘要
Progress has been made in molecular, cellular and biochemical
pharmacology of serotonin (5-HT) receptors yet their functional
significance is uncertain. The GENERAL OBJECTIVE is to use selective
pharmacologic agents to assess forebrain 5-HT receptor subtypes in vivo.
The HYPOTHESIS is that selective activation of blockade of 5-HT receptor
subtypes in discrete brain regions will elicit unique patterns of
autonomic, hemodynamic and neuroendocrine responses to affect
cardiovascular function. The SPECIFIC AIMS are to microinject drugs into
the anterior hypothalamus, paraventricular nucleus, the medial preoptic
area and central amygdala in conscious, unrestrained rats to: 1) DESCRIBE
ROLES FOR FOREBRAIN 5-HT1A,5-HT2, and 5-HT3 RECEPTORS IN CARDIOVASCULAR
FUNCTION, AND 2) DETERMINE NEURAL AN/OR HORMONAL MEDIATORS OF THE
RESPONSES. The 5-HT agonists to be used primarily are 8-OH-DPAT [8-
hydroxy-2-di-nu-propylamino) tetralin] for 5-HT1A receptors, DOI
[(plus/minus)-1-(2-5-dimethoxy-4-iodophenyl)-2-aminopropane HC1] for 5-
HT2/1C receptors and 2-methyl 5-HT for 5-HT3 receptors. Other agonists
to provide more detailed receptor characterizations may include
flesinoxan and 5-carboxamidotryptamine (5-HT1A), DOB [(plus/minus)-1-(2-
5-dimethoxy-4-bromophenyl)-2-aminopropane HBr] (5-HT2/1C) and
phenylbiguanide(5-HT3). The antagonists to be used primarily are
spiperone for 5-HT1A receptors, ketanserin for 5-HT2 receptors, and ICS
205-930 for 5-HT3 receptors. Again, more detailed characterizations may
include the use of (-)pindolol, (+) pindolol, and methiothepin (5-HT1A),
LY 53857 and spiperone (5-HT2/1C, and MDL 72222 and ondansetron (5-HT3).
The appropriate use of these drugs in conjunction with a description of
diffusional distances using autoradiographic techniques as well as the
ability of autonomic and hormone antagonists to alter responses will
allow an quantitative in vivo assessment of mechanisms by which 5-HT
receptor subtypes in the forebrain regulate arterial pressure, heart
rate, cardiac output and renal, iliac and superior mesenteric blood
flows. To separate reflex from direct responses the serotonergic drugs
will be microinjected following chronic surgical baroreceptor
deafferentation. Overall, the experiments will provide detailed
information on brain regions, receptor subtypes and neurohumoral
mechanisms by which 5-HT receptors regulate cardiovascular homeostasis.
These studies will provide significant in vivo data regarding the
function of 5-HT receptor subtypes in discrete forebrain areas as an
extension of the in vitro biochemical, cellular and molecular
pharmacology.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHARMACOLOGY OF FOREBRAIN SEROTONIN RECEPTORS
-
批准号:3416649
-
项目类别:
-
资助金额:$0.37万
-
财政年份:1993
-
负责人:RICHARD H ALPER
-
依托单位:
PHARMACOLOGY OF FOREBRAIN SEROTONIN RECEPTORS
-
批准号:2267879
-
项目类别:
-
资助金额:$12.73万
-
财政年份:1993
-
负责人:RICHARD H ALPER
-
依托单位:
PHARMACOLOGY OF FOREBRAIN SEROTONIN RECEPTORS
-
批准号:2267878
-
项目类别:
-
资助金额:$12.62万
-
财政年份:1993
-
负责人:RICHARD H ALPER
-
依托单位:
RENAL NERVES AND CENTRAL MONOAMINES IN HYPERTENSION
-
批准号:3449463
-
项目类别:
-
资助金额:$5.08万
-
财政年份:1986
-
负责人:RICHARD H ALPER
-
依托单位:
RENAL NERVES AND CENTRAL MONOAMINES IN HYPERTENSION
-
批准号:3449462
-
项目类别:
-
资助金额:$4.48万
-
财政年份:1986
-
负责人:RICHARD H ALPER
-
依托单位:
RENAL NERVES AND CENTRAL MONOAMINES IN HYPERTENSION
-
批准号:3449464
-
项目类别:
-
资助金额:$4.06万
-
财政年份:1986
-
负责人:RICHARD H ALPER
-
依托单位:
LOCAL REGULATION OF ADRENAL CORTICOSTERONE SECRETION
-
批准号:3867907
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:RICHARD H ALPER
-
依托单位:
LOCAL REGULATION OF ADRENAL CORTICOSTERONE SECRETION
-
批准号:3889164
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:RICHARD H ALPER
-
依托单位:
RENAL NERVES AND CENTRAL MONOAMINES IN HYPERTENSION
-
批准号:3951913
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:RICHARD H ALPER
-
依托单位:
海外基金